Sun Pharma Advanced Research Company reports standalone net loss of Rs 94.19 crore in the June 2019 quarter
Sun Pharma Advanced Research Company reports standalone net loss of Rs 9.35 crore in the March 2019 quarter
Sun Pharma Advanced Research Company (SPARK) reported a net loss of Rs 63.16 crore in Q2 September 2019, higher than net loss of Rs 2.58 crore Q2 September 2018.
Revenue from operations slumped 71.98% to Rs 17.19 crore in Q2 September 2019 over Q2 September 2018.
The stock fell as much as 5.48% to hit an intraday low of Rs 135.50. The stock was currently trading higher by 1.85% at Rs 146.
On the BSE, 3.96 lakh shares were traded in the counter so far compared with average daily volumes of 1.29 lakh shares in the past two weeks. The stock hit a high of Rs 151.9 so far during the day.
Sun Pharma Advanced Research Company (SPARC) is a clinical stage bio-pharmaceutical company.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)